Superworth

Neurocrine Biosciences price to book ratio NBIX

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
3.9×
10-year median
7.4×
Against its 10-year history
1st
percentile: 0 is its lowest day, 100 its highest
10-year range
3.5× to 29.5×
Peer median
6.1×

Neurocrine Biosciences' price to book ratio is 3.9× as of Oct 23, 2026.

That is below its ten-year median of 7.4×, lower than on 99% of days in the last ten years.

Over that time it ranged from 3.5× in Apr 2025 to 29.5× in Aug 2018.

The median for 10 biotech stocks of a similar size is 6.1×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.9×3.7×5.2×
20254.8×3.5×5.7×
20245.2×4.4×7.0×
20236.5×5.3×7.7×
20227.4×5.3×7.9×
20216.0×5.6×13.6×
202011.1×10.3×18.0×
201917.4×14.5×19.6×
201813.9×13.9×29.5×
201719.8×10.0×19.8×
20169.6×6.9×13.0×
201510.9×6.3×16.1×
20147.7×4.0×10.3×
20134.9×3.9×7.9×
20123.4×3.0×9.9×
20118.1×5.7×16.7×

Against its peers

Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.

CompanyPrice to book ratio
NBIXNeurocrine Biosciences3.9×
HALOHalozyme Therapeutics99.3×
EXELExelixis8.7×
TECHBIO-TECHNE5.4×
RGENRepligen4.7×
KRYSKrystal Biotech6.8×
INCYIncyte3.7×
UTHRUnited Therapeutics3.9×
ALNYAlnylam Pharmaceuticals22.1×
ONCBeOne Medicines8.3×
REGNRegeneron Pharmaceuticals2.6×
Peer median6.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Neurocrine Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.